Rui Lu, MD
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1356308332
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,639 of the $11,848 with a category attached, or 89.8%. It is spread thinly across 35 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.
Across 391 payments — averaging $30.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Sanofi-aventis U.S. LLC$2K
- Lilly USA, LLC$2K
- Senseonics, Incorporated$1K
- AstraZeneca$703
- AbbVie$439
- plus $4K from 29 others
What the payments were for
- Speaking & faculty fees$1,20010%
- Food & beverage$10,63990%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 84 | $2,626 |
| Sanofi-aventis U.S. LLC | 47 | $1,592 |
| Lilly USA, LLC | 75 | $1,525 |
| Senseonics, Incorporated | 3 | $1,200 |
| AstraZeneca | 13 | $703 |
| AbbVie | 21 | $439 |
| Mannkind Corporation | 23 | $361 |
| Boehringer Ingelheim | 14 | $339 |
| Amgen(2 entities) | 12 | $330 |
| Ascensia Diabetes Care US Inc. | 11 | $314 |
| Bayer | 8 | $301 |
| Abbott | 13 | $281 |
| Insulet Corporation | 5 | $272 |
| Corcept Therapeutics | 7 | $255 |
| Xeris Pharmaceuticals, Inc. | 13 | $225 |
| Medtronic(2 entities) | 6 | $179 |
| Zealand Pharma US, Inc. | 3 | $158 |
| Antares Pharma, Inc. | 3 | $125 |
| Amarin Pharma, Inc. | 5 | $89 |
| Dexcom, Inc. | 3 | $88 |
| BETA Bionics, Inc. | 3 | $70 |
| Tandem Diabetes Care, Inc. | 2 | $53 |
| Merck | 3 | $46 |
| Cequr Corporation | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Embecta Corp. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,848 in reported general payments places this provider in the 80th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 398 | $648,385 |
| MounjaroTirzepatide | 278 | $515,624 |
| OzempicSemaglutide | 239 | $427,025 |
| Tresiba Flextouch U-200Insulin Degludec | 167 | $140,230 |
| JardianceEmpagliflozin | 81 | $122,631 |
| FarxigaDapagliflozin Propanediol | 54 | $82,126 |
| ProliaDenosumab | 31 | $53,088 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $52,016 |
| JanuviaSitagliptin Phosphate | 64 | $45,747 |
| Humalog Kwikpen U-100Insulin Lispro | 139 | $37,981 |
| RybelsusSemaglutide | 16 | $35,434 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $34,298 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 220 | $25,102 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $22,767 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $22,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,525 | $1,165,980687 claims |
| Novo NordiskOzempic, Rybelsus | $2,626 | $462,459255 claims |
| Boehringer IngelheimJardiance | $339 | $122,63181 claims |
| AstraZenecaFarxiga | $703 | $82,12654 claims |
| AmgenProlia | $330 | $53,08831 claims |
| MerckJanuvia | $46 | $45,74764 claims |
| AbbVieSynthroid | $439 | $4,66152 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $4,403313 claims |
| Sanofi-aventis U.S. LLCAdmelog | $1,592 | $1,94011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
Other endocrinology, diabetes & metabolism in Washington
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
- Mark SklarWashington$14K
- Sabyasachi SenWashington$12K
- Qudsia HussainWashington$9K
- Jerold ShareWashington$7K
- Leonard WartofskyWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.